• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.

作者信息

Zhao Yao, Fang Chao, Zhang Qi, Zhang Ruxue, Zhao Xiangbo, Duan Yinkai, Wang Haofeng, Zhu Yan, Feng Lu, Zhao Jinyi, Shao Maolin, Yang Xiuna, Zhang Leike, Peng Chao, Yang Kailin, Ma Dawei, Rao Zihe, Yang Haitao

机构信息

Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.

State Key Laboratory of Bioorganic & Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200032, China.

出版信息

Protein Cell. 2022 Sep;13(9):689-693. doi: 10.1007/s13238-021-00883-2. Epub 2021 Oct 22.

DOI:10.1007/s13238-021-00883-2
PMID:34687004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8533666/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bed/9233717/3bae559a254c/13238_2021_883_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bed/9233717/3bae559a254c/13238_2021_883_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bed/9233717/3bae559a254c/13238_2021_883_Fig1_HTML.jpg

相似文献

1
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.严重急性呼吸综合征冠状病毒2型主要蛋白酶与蛋白酶抑制剂PF-07321332复合物的晶体结构
Protein Cell. 2022 Sep;13(9):689-693. doi: 10.1007/s13238-021-00883-2. Epub 2021 Oct 22.
2
Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.探讨表观遗传药物作为 SARS-CoV-2 主蛋白酶潜在抑制剂的研究：对接和 MD 模拟研究。
J Biomol Struct Dyn. 2024 Aug;42(13):6892-6903. doi: 10.1080/07391102.2023.2236714. Epub 2023 Jul 17.
3
Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.基于监督分子动力学（SuMD）对 SARS-CoV-2 主要蛋白酶抑制剂 PF-07321332 作用机制的研究
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1646-1650. doi: 10.1080/14756366.2021.1954919.
4
In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease.伊维菌素和奈玛特韦抑制剂与 SARS-CoV-2 主蛋白酶相互作用的计算机比较分析。
Biomolecules. 2024 Jun 25;14(7):755. doi: 10.3390/biom14070755.
5
Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease.PF-07321332 抑制剂与 SARS-CoV-2 主蛋白酶非共价相互作用的特性。
J Mol Graph Model. 2022 Jan;110:108042. doi: 10.1016/j.jmgm.2021.108042. Epub 2021 Oct 5.
6
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.通过分子动力学和结合自由能模拟探索 PF-07321332 SARS-CoV-2 蛋白酶抑制剂的结合机制。
Int J Mol Sci. 2021 Aug 24;22(17):9124. doi: 10.3390/ijms22179124.
7
Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study.尼马瑞韦（PF-07321332）-3CL 样 SARS-CoV-2 蛋白酶复合物的结构见解：配体高斯加速分子动力学研究。
Phys Chem Chem Phys. 2022 Sep 28;24(37):22898-22904. doi: 10.1039/d2cp02882d.
8
Design of novel and highly selective SARS-CoV-2 main protease inhibitors.新型高选择性 SARS-CoV-2 主蛋白酶抑制剂的设计。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0056224. doi: 10.1128/aac.00562-24. Epub 2024 Sep 3.
9
Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.甘草酸与氨基酸甲酯缀合物靶向主蛋白酶，对野生型和奈玛特韦耐药的 SARS-CoV-2 变异株均具有抗病毒活性。
Antiviral Res. 2024 Jul;227:105920. doi: 10.1016/j.antiviral.2024.105920. Epub 2024 May 29.
10
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.新型冠状病毒主蛋白酶抑制剂的最新进展：从奈玛特韦到未来展望。
Biomolecules. 2023 Sep 2;13(9):1339. doi: 10.3390/biom13091339.

引用本文的文献

1
Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach.靶向严重急性呼吸综合征冠状病毒2主蛋白酶：一种药效团和分子建模方法。
J Mol Model. 2025 Jul 29;31(8):222. doi: 10.1007/s00894-025-06441-5.
2
Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease.克服严重急性呼吸综合征冠状病毒2（SARS-CoV-2）非结构蛋白5（nsp5）蛋白酶中奈玛特韦耐药机制的策略。
Sci Adv. 2025 Jun 6;11(23):eadv8875. doi: 10.1126/sciadv.adv8875.
3
Structural basis for varying drug resistance of SARS-CoV-2 M E166 variants.

本文引用的文献

1
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.静脉注射冠状病毒 3CL 蛋白酶抑制剂的临床前特征，用于治疗 COVID19 的潜在药物。
Nat Commun. 2021 Oct 18;12(1):6055. doi: 10.1038/s41467-021-26239-2.
2
Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.在高度接种疫苗的医疗系统工作人员中出现的新冠病毒感染复发现象。
N Engl J Med. 2021 Sep 30;385(14):1330-1332. doi: 10.1056/NEJMc2112981. Epub 2021 Sep 1.
3
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.
新冠病毒M E166变体不同耐药性的结构基础
mBio. 2025 Jul 9;16(7):e0262424. doi: 10.1128/mbio.02624-24. Epub 2025 Jun 2.
4
Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 M mutants and MERS-CoV M.博富特韦对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）M突变体和中东呼吸综合征冠状病毒（MERS-CoV）M的抑制效果及结构见解
Commun Biol. 2025 Mar 25;8(1):493. doi: 10.1038/s42003-025-07929-9.
5
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.基于肽的药物研发进展：递送平台、治疗药物与疫苗
Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5.
6
Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.探索新型冠状病毒主要蛋白酶的共价抑制剂：从拟肽到新型骨架
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2460045. doi: 10.1080/14756366.2025.2460045. Epub 2025 Feb 6.
7
An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV-2 M.严重急性呼吸综合征冠状病毒2中奈玛特韦（帕罗韦德）耐药性的研究
ACS Bio Med Chem Au. 2024 Oct 8;4(6):280-290. doi: 10.1021/acsbiomedchemau.4c00045. eCollection 2024 Dec 18.
8
Covalent Proximity Inducers.共价接近诱导剂
Chem Rev. 2025 Jan 8;125(1):326-368. doi: 10.1021/acs.chemrev.4c00570. Epub 2024 Dec 18.
9
Single-dose tolerability and pharmacokinetics of leritrelvir in Chinese patients with hepatic impairment and healthy matched controls.来瑞特韦在中国肝功能损害患者及健康匹配对照中的单剂量耐受性和药代动力学
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0137724. doi: 10.1128/aac.01377-24. Epub 2024 Dec 17.
10
SARS-CoV-2 Resistance to Small Molecule Inhibitors.严重急性呼吸综合征冠状病毒2对小分子抑制剂的耐药性。
Curr Clin Microbiol Rep. 2024 Sep;11(3):127-139. doi: 10.1007/s40588-024-00229-6. Epub 2024 Jun 24.
COVID-19 疫苗研发进展：病毒、疫苗和变体与疗效、有效性和逃逸。
Nat Rev Immunol. 2021 Oct;21(10):626-636. doi: 10.1038/s41577-021-00592-1. Epub 2021 Aug 9.
4
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.考虑用于发现和开发针对 SARS-CoV-2 感染的 3-糜蛋白酶样半胱氨酸蛋白酶抑制剂。
Curr Opin Virol. 2021 Aug;49:36-40. doi: 10.1016/j.coviro.2021.04.006. Epub 2021 Apr 27.
5
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.高通量筛选鉴定出已上市药物为 SARS-CoV-2 PLpro 抑制剂。
Protein Cell. 2021 Nov;12(11):877-888. doi: 10.1007/s13238-021-00836-9. Epub 2021 Apr 17.
6
Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19.以新型冠状病毒主要蛋白酶为靶点治疗新冠肺炎的药物研发新进展
Front Mol Biosci. 2020 Dec 4;7:616341. doi: 10.3389/fmolb.2020.616341. eCollection 2020.
7
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.酮基共价抑制剂冠状病毒 3CL 蛋白酶的发现，为 COVID-19 的潜在治疗提供了可能。
J Med Chem. 2020 Nov 12;63(21):12725-12747. doi: 10.1021/acs.jmedchem.0c01063. Epub 2020 Oct 15.
8
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.博赛泼维与 GC376 均可通过靶向作用于 SARS-CoV-2 的主蛋白酶而有效抑制该病毒。
Nat Commun. 2020 Sep 4;11(1):4417. doi: 10.1038/s41467-020-18233-x.
9
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.基于结构的针对 SARS-CoV-2 主蛋白酶的抗病毒药物候选物的设计。
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
10
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.